David Nicol
David Nicol
Royal Marsden Hospital/Institute of Cancer Research/University of Queensland
Verified email at
Cited by
Cited by
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ...
Nature genetics 46 (3), 225-233, 2014
Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, T Chambers, JI Lopez, D Nicol, ...
Cell 173 (3), 581-594. e12, 2018
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic
A Sud, ME Jones, J Broggio, C Loveday, B Torr, A Garrett, DL Nicol, ...
Annals of Oncology 31 (8), 1065-1074, 2020
Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
S Turajlic, H Xu, K Litchfield, A Rowan, S Horswell, T Chambers, ...
Cell 173 (3), 595-610. e11, 2018
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
A Sud, B Torr, ME Jones, J Broggio, S Scott, C Loveday, A Garrett, ...
The Lancet Oncology 21 (8), 1035-1044, 2020
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
CS Cooper, R Eeles, DC Wedge, P Van Loo, G Gundem, LB Alexandrov, ...
Nature genetics 47 (4), 367-372, 2015
Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal
TJ Mitchell, S Turajlic, A Rowan, D Nicol, JHR Farmery, T O’Brien, ...
Cell 173 (3), 611-623. e17, 2018
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
Non‐melanoma skin cancer risk in the Queensland renal transplant population
HM Ramsay, AA Fryer, CM Hawley, AG Smith, DL Nicol, PN Harden
British Journal of Dermatology 147 (5), 950-956, 2002
The effect of obesity on renal transplant outcomes
DW Johnson, NM Isbel, AM Brown, TD Kay, K Franzen, CM Hawley, ...
Transplantation 74 (5), 675-681, 2002
Repeat urethrotomy and dilation for the treatment of urethral stricture are neither clinically effective nor cost-effective
TJ Greenwell, C Castle, DE Andrich, JT MacDonald, DL Nicol, AR Mundy
The Journal of urology 172 (1), 275-277, 2004
Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial
HJ Green, KI Pakenham, BC Headley, J Yaxley, DL Nicol, PN Mactaggart, ...
BJU international 90 (4), 427-432, 2002
Mutational signatures of ionizing radiation in second malignancies
S Behjati, G Gundem, DC Wedge, ND Roberts, PS Tarpey, SL Cooke, ...
Nature communications 7 (1), 1-8, 2016
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers
M Takahashi, XJ Yang, J Sugimura, J Backdahl, M Tretiakova, CN Qian, ...
Oncogene 22 (43), 6810-6818, 2003
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ...
Nature genetics 50 (5), 682-692, 2018
Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display
FK Rae, SA Stephenson, DL Nicol, JA Clements
International Journal of Cancer 88 (5), 726-732, 2000
Vascular endothelial growth factor expression is increased in renal cell carcinoma
D Nicol, SI Hii, M Walsh, B Teh, L Thompson, C Kennett, D Gotley
The Journal of urology 157 (4), 1482-1486, 1997
Bone and prostate cancer cell interactions in metastatic prostate cancer
I Vela, L Gregory, EM Gardiner, JA Clements, DL Nicol
BJU international 99 (4), 735-742, 2007
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer …
TL Veveris-Lowe, MG Lawrence, RL Collard, L Bui, AC Herington, ...
Endocrine-related cancer 12 (3), 631-643, 2005
The system can't perform the operation now. Try again later.
Articles 1–20